Application of silver nanoparticles in the treatment of central serous chorioretinopathy

被引:1
|
作者
Chen, Yao [1 ]
Su, Fanfan [1 ]
Su, Bo [2 ]
机构
[1] Yangtze Univ, Jingzhou Cent Hosp, Clin Med Coll 2, Dept Ophthalmol, Jingzhou 434020, Hubei, Peoples R China
[2] Yangtze Univ, Sch Med, Dept Pathol, Jingzhou 434023, Hubei, Peoples R China
关键词
Silver Nanoparticle; Central Serous Chorioretinopathy; Treatment; COMPOSITE FILM; DNA; NANOCLUSTERS; FLUORESCENCE;
D O I
10.1166/mex.2023.2353
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The purpose of this study was to explore the therapeutic effect of silver nanoparticles in the treatment of central serous chorioretinopathy (CSC). After the establishment of CSC in New Zealand rabbits (n = 128), the animals were treated with iodized lecithin tablets by gavage (ILT only, n = 64) or ILT gavage followed by injection of silver nanoparticles into the vitreous cavity (SN, n = 64). The sum retinal layer thickness of SN group before gavage was lower than that of ILT group, and the total retinal thickness of SN group after gavage was also lower than that of ILT group. There were interaction effects between groups and time IP: 217 163 11 .10 On Tue 18 Apr 2023 14:08:13 (Fgroup effect = 42.570, Ftime effect = 19.250, Copyright: Finteraction American effect = 2.885,Scien allific <Publishers0.05).Electroretinograms showed lower peak latency in oscillatory potential (OP1, OP2, and OP3) in the SN group than in the ILT group before and after gavage (intergroup effect: F1 = 40.280, F2 = 52.760, F3 =133.700; time effect: F1 =10.330, F2 = 9.082, F3 = 93.760; interaction effects: F1 = 4.204, F2 = 3.059, F3 = 12.260; all P < 0.05). The b-wave amplitudes and total amplitudes were higher in the SN group than in the ILT group before and after gavage (intergroup effect: F1 = 10.540, F2 = 13.270; time effect: F1 = 25.910, F2 = 35.120; interaction effects: F1 = 2.817, F2 = 5.264; all P < 0.05). No significant differences in intraocular pressure were observed, and there were no interaction effects (Fintergroup effect = 0.046, Ftime effect = 0.001, Finteraction effect = 0.027, all P > 0.05). We conclude that silver nanoparticles provide a significant therapeutic effect on CSC in rabbits, ensuring the integrity of retinal morphology, structure, function, and limiting damage to visual function.
引用
收藏
页码:274 / 282
页数:9
相关论文
共 50 条
  • [41] Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy
    Huang, W-C
    Chen, W-L
    Tsai, Y-Y
    Chiang, C-C
    Lin, J-M
    EYE, 2009, 23 (02) : 488 - 489
  • [42] Treatment Outcomes of Simple and Complex Central Serous Chorioretinopathy
    Kamao, Hiroyuki
    Goto, Katsutoshi
    Ouchi, Tatsuhiro
    Shirakawa, Yuki
    Hiraki, Ryutaro
    Mizukawa, Kenichi
    Miki, Atsushi
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (05)
  • [43] Spironolactone in the treatment of central serous chorioretinopathy – a case series
    T. R. Herold
    K. Prause
    A. Wolf
    W. J. Mayer
    M. W. Ulbig
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252 : 1985 - 1991
  • [44] The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab
    Lee, Shelly T.
    Adelman, Ron A.
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2011, 27 (06) : 611 - 614
  • [45] Guidelines for the care and treatment of patients with central serous chorioretinopathy
    Stur, Michael
    Ansari-Shahrezaei, Siamak
    Haas, Anton
    Tittl, Michael
    SPEKTRUM DER AUGENHEILKUNDE, 2016, 30 (01) : 39 - 47
  • [46] Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy
    Meyerle, Catherine B.
    Freund, K. Bailey
    Bhatnagar, Pawan
    Shah, Viral
    Yannuzzi, Lawrence A.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (07): : 943 - 946
  • [47] The stress response as a target for treatment of central serous chorioretinopathy
    Bujarborua, Dhiren
    Borooah, Shyamanga
    Dhillon, Baljean
    EXPERT REVIEW OF OPHTHALMOLOGY, 2013, 8 (05) : 457 - 468
  • [48] Topical brinzolamide for the treatment of idiopathic central serous chorioretinopathy
    LOntiveros-Orozco, I
    Garcia-Franco, R
    Levine-Berebichez, A
    Celis-Suazo, B
    Rojas-Juarez, S
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U204 - U204
  • [49] Antidepressants in treatment of central serous chorioretinopathy associated with stress
    Dudani, Ajay, I
    Dudani, Anadya A.
    Dudani, Krish
    Dudani, Anupam A.
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2024, 72 (04) : 607 - 608
  • [50] A Case of Central Serous Chorioretinopathy after Tadalafil Treatment
    Yoon, Yo Sep
    Lee, Seunghwan
    Woo, Je Moon
    Min, Jung Kee
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2018, 59 (01): : 93 - 97